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1. Introduction 
Schistomiasis is a disease caused by digenetic trematodes that belong to the family 
Schistosomatoidae. Five species of Schistosomes are involved in human infection. The three 
principal agents are Schistosoma mansoni and S. japonicum which are responsible for intestinal 
schistosomiasis and S. haematobium, the aetiologic agent of urinary schistosomiasis. The 
other two species responsible for intestinal disease though with low frequency are S. 
intercalatum and S. mekongi. The disease affects about 240 million people worldwide while an 
estimated 779 million people (more than 10% of the world population) are at the risk of 
infection. About 120 million people infected with schistosomiasis are estimated to be 
symptomatic while about 20 million develop severe diease.The disability-adjusted life years 
(DALYs) due to schistosomiasis is about 1.7-4.5 million while between 150,000 to 280,000 
people are known to die as a consequence of the disease per year. Africa accounts for 85% of 
the disease burden (Steinmann et al., 2006; WHO, 2002). Although, schistosomiasis is a rural 
focal disease typically associated with poor rice farmers and fishermen in the tropics, it is 
increasingly been reported among Europeans with a history of travel to endemic areas in 
Africa and Asia. It is transmitted by snails found in cercariae infested fresh water streams. 
Snails belonging to the species Bulinus, Biomphalaria and Onchomelania are the vectors of S. 
haematobium, S. mansoni and S. japonicum respectively. 
The cardinal objective in the control of schistosomiasis is the reduction of morbidity and 
mortality to levels below public health significance. Over the years, emphasis has shifted 
from the non-realizable goal of eradication to the more realistic goal of morbidity control. In 
this context, Gemmel et al (1986), defined “a control programme” as the “implementation of 
specific measures by a disease control authority to limit the incidence of the disease”. Such 
implementation may involve specific technical interventions and perhaps legislation to 
enforce compliance. The success of this type of approach is predicated on an accurate 
ecological diagnosis, that is, a diagnosis of the human community, its parasitological 
characteristics, its physico-geographical environmental attributes and man’s behavioural 
attitudes and customs (Davis, 1981).  
The enormous morbidity associated with schistosomiasis which ranks it next to malaria in terms 
of public health significance re-emphasises the need for a coordinated and sustainable means for 
the control of the disease. There is a consensus of opinion that the control of the disease should be 
integrated. In this model of control, King (2009) identified the applicable approaches as:  
 Population based chemotherapy 
 Snail control which involves habitat modification and use of plant and chemical 
molluscicides, 
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 Proper treatment of sewage,  
 Good environmental engineering designs for the development of irrigation and 
hydroelectric schemes to limit the availability of breeding grounds for the snail vectors 
 Provision of clean and safe piped water and  
 Massive health education and mobilization of the population to claim ownership of the 
programme 
In this Chapter, the various methods of control of schistosomiasis listed above are reviewed 
with special emphasis on those that are accessible, affordable, acceptable and capable of 
yielding high levels of sensitivity and specificity. Chemotherapy which is the most feasible 
method of morbidity control of the disease particularly in the short-term is examined in more 
details. In the process, the hindrances to an effective integrated control approach are identified 
while recommendations on the way forward are proffered. There is no doubt that vaccination 
holds the key for the cost effective and sustainable control of infectious diseases including 
schistosomiasis. The progress made in the identification of probable candidate antigen 
molecules for the control of schistosomiasis is also examined. The basis of this composite 
approach is to gradually reduce the morbidity due to schistosomiasis. This is likely to result in 
the drastic reduction in the number of infected subjects and environmental egg pollution. 
Where this is sustained, infection would no longer be of public health significance. 
2. Control of schistosomiasis 
The first control programme for schistosomiasis was initiated in 1913 in Egypt where both 
local people and stationed soldiers were heavily infected. This was anchored on snail 
control. The effectiveness of the programme was based on the numbers of snails killed and 
not reductions in the numbers of infections (Jordan, 2000). Mass treatment with tartar emetic 
was also an integral part of the process although the results were not encouraging. About 
the 1930s, sanitation was incorporated in the programme, but still the results were not 
convincing (Jordan & Rosenfield, 1983). Following the elucidation of the life cycle of 
Schistosomes by Lieper during the first years of the first world war, snail control and mass 
treatment became the model of control efforts. Jordan (2000) noted that together with 
recommendations on a number of environmental control measures, Leiper considered it 
possible to eradicate the disease without the cooperation of the infected individuals by 
destroying the snail intermediate host. Blas et al (1989) reports that the first control 
programme that integrated research and systematic monitoring of its effect was 
implemented in Lyte in the Philippines from 1953 to 1962 with the help of the WHO. The 
initial objective of the schistosomiasis control was aimed at stopping transmission. This 
could hardly be achieved and remains elusive even up till today. 
The WHO Expert Committee on Epidemiology and Control of Schistosomiasis took a holistic 
approach at the control of the disease and noted that “comprehensive understanding of the 
environment, demographic, social, human behavioural and economic factors” in 
schistosomiasis is essential for the design of control programmes that are successful in the long 
run (Kloos, 1985). With the advent of praziquantel (PZQ) as a safe and efficacious drug for the 
treatment of schistosomiasis, the WHO in 1991 reinforced its 1984 recommendation to shift 
from transmission control (focusing on the prevalence of infection) to morbidity control 
(laying emphasis on intensity of infection) (Bruun and Aagaard-Hansen, 2008). Morbidity 
control will not only reduced the number of people infected but it will also drastically reduce 
environmental contamination with the eggs even when cure is not attained. A drastic 
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reduction of the pollution of the environment with the eggs would also reduce the chances of 
transmission. Should this occur at a level below public health importance, the probability of 
eventually elimination of disease is certain with a sustained integrated approach 
3. Chemotherapeutic control of schistosomiasis 
Of all the methods of control listed above, chemotherapy is the only one that is widely used 
presently in endemic areas for the control of morbidity due to schistosomiasis. Among the 
first group of drugs used for the treatment of schistosomiasis included; Antimonials, 
Niridazole, Hycanthone, Lucanthone, Oxamniquine and albendazole. PZQ is currently used 
for the treatment of all the species while metrifonate is active against S. haematobium only. 
Recently, artemisinins earlier synthesized for the treatment of malaria infection is being 
used in some endemic communities to treat schistosomiasis. The WHO (1993) identified four 
approaches in the administration of chemotherapy programme namely; 
i. Mass treatment: treatment of the entire population. This is often limited by availability 
of finance. 
ii. Selective population treatment: treatment of infected persons identified by a diagnostic 
survey of the whole population 
iii. Selective group treatment: treatment of all or infected members of a high risk age or 
occupational group 
iv. Phased treatment: use of the above strategies in a sequence of progressively greater 
selectivity. 
It is recommended that treatment should be administered to schoolchildren who are the 
most vulnerable group through the school system. The outcome of basing treatment on the 
school system is bound to give variable results. In an area endemic for urinary 
schistosomiasis in Nigeria, Useh and Ejezie (1999a) showed that relying on the school 
system alone to deliver control programme may substantially limit the outcome of control of 
schistosomiasis. The rates of regular, irregular and non school attendance were 69.1%, 5.1% 
and 25.8% respectively. Out of school children were more associated (90.7%) with S. 
haematobium infection than those in school (86.8%). The authors recommended a dual 
method of control that would incorporate the integration of recognized local authorities in 
areas with moderate school attendance like their study area as lack of treatment of infected 
out of school children would ensure continuous contamination and re-infection. (See Table 1) 
 
Gender Regular School 
Pupils, No(%) 
Irregular 
School Pupils, 
No(%) 
Children Out of 
School, No(%) 
Total 
Male 889(76.6) 50(4.3) 222(19.1) 1161 
Female 699(61.4) 67(5.9) 372(32.7) 1138 
X2 58.02 2.77 55.86 NA 
Odds Ratio 2.020 0.72 0.48 NA 
95% CI 1.69-2.42 0.49-1.04 0.4-0.58 NA 
P <0.0001 >0.05 <0.0001 NA 
(Adopted from Useh & Ejezie, 1999a ) 
Table 1. Frequency of school attendance and non-attendance by sex of school-age children in 
Adim, Nigeria. 
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This recommendation is supported by a study conducted in Tanzania on the effect of 
community-directed treatment approach (ComDT) versus the school-based treatment 
approach on the prevalence and intensity of schistosomiasis and soil-transmitted 
helminthiasis (STH) among schoolchildren (Massa et al.,2009). The prevalence of S. 
haematobium and Hookworm infections were significantly lower in the ComDT approach 
villages compared to the school-based approach villages (10.6 versus 16.3%, P = 0.005 and 
2.9 versus 5.8%, P = 0.01, respectively). 
3.1 PZQ 
3.1.1 Biochemical properties and pharmacokinetics 
PZQ is the drug of choice for the treatment of schistosomiasis. It is a broad spectrum anti-
schistosomal which is principally active against the adult stage of all the schistosome species 
infective to man. It is a 2-cyclohexycarbonyl 1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a 
Isoquinolin-4one) compound with a melting point at 136-140C. It was developed in the 
laboratories for Parasitological Research of Bayer AG and Merck KGaA in Germany (Elbert and 
Darmstadt) in the mid 1970s. It has a molecular mass of 312.411 with a serum half life of 0.8 to 1.5 
hours in adults with normal liver and kidney function and is mainly excreted in urine. PZQ is a 
white crystalline powder with bitter taste. It is stable under normal storage conditions. Although, 
it is insoluble in water, it is soluble in chloroform, dimethylsulfoxide and ethanol. It is sold as a 
racemate mixture consisting of equal parts of ‘laevo’ and ‘dextro’ isomers, of which only the 
laevo component displays anti-schistosomal properties. 
The recommended dose of PZO is 40 mg/kg body weight. The drug is available as a 600mg 
tablet. The quality of PZQ (proprietary and generic) currently available in the market is 
quite high. Thirty four PZQ samples from different manufacturers were collected at the user 
level in various countries and subjected to quantitative analysis of active ingredient, purity, 
disintegration and dissolution in accordance with established pharmacopoeial standards. 
The results showed that most of the samples were of high quality except two samples from 
the same manufacturer that had no PZQ (Sulaiman et al., 2001). About 90% of the damage 
done to organ function are known to reverse six months following the administration of 
PZQ. Although it is exceptionally well tolerated, reported side –effects include abdominal 
discomfort, nausea, headache, dizziness, drowsiness and pyrexia especially in subjects with 
high egg counts (Andrews,1981). 
3.1.2 Mode of action of PZO 
The mode of action of PZQ has been extensively reviewed elsewhere (Doenhoff et al., 2008 & 
20009). The exact mechanisms of action of PZQ is still poorly understood. PZQ is known to 
induce rapid calcium influx that distort the morhoplogy and physiology of schistosome. 
Jeziorski and Greenberg (2006) showed that the B subunits of voltage-gated Ca2+ channels is 
the prime molecular target of PZQ. It has recently been reported that cytochalasin D 
abolished the schistosomicicidal activity of PZQ but calcium influx into PZQ exposed 
schistosomes was not halted. This result therefore raises doubts whether calcium influx is 
essential in the antischistosomal activity of PZQ (Pica-Mattoccia et al.,2008). PZQ induces 
contraction of schistosomes which manifest in paralysis in the contracted state. 
Additionally, vacuolation and blebbing near and on the surface of the worm have equally 
been reported (Pax et al., 1978). 
PZQ is known to increase exposure of antigens on the worm surface. It is believed that 
this in turn renders the worm more susceptible to antibody attack. Doenhoff et al (1987) 
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inferred that this drug induced antigen exposure is assumed to account for the synergistic 
effect between PZQ and the host antibodies in killing worms invivo. Recently, it has been 
shown that PZQ seems to interfere with adenosine uptake in cultured worms. This may 
have therapeutical relevance given that the schistosome is unable to synthesize purines 
such as adenosine de novo. It may be assumed that the drug interferes with schistosome’s 
obligate need to acquire adenosine from its host. This is confounding as a relationship 
between Ca2+ channels and adenosine receptors has been demonstrated in cells of some 
other animals and adenosine can antagonize Ca2+ release. This informs the inference 
drawn by Angelucci et al (2007) that PZQ-induced Ca2+ influx and adenosine receptor 
blockade may be connected.  
3.1.3 Field studies on the efficacy and effectiveness of PZQ 
It is important to understand the difference between efficacy and effectiveness as 
applicable to anthelminthic drugs in field trials. The WHO (2002) defined efficacy as the 
“effect of a drug against an infectious agent, in isolation and under ideal conditions” 
while effectiveness refers to the “effect of the drug against an infective agent under 
operational conditions”. Following from the above, effectiveness may be influenced by 
factors such as patient compliance with treatment, and by ecological, immunological, or 
epidemiological factors confounding by ongoing disease transmission. Thus the main 
markers of effectiveness of large-scale deworming exercise is the general improvement in 
health status of the population at risk and also taking into consideration other important 
variables such as cost of drug delivery, accessibility and acceptability of treatment, and 
sustainability. Efficacy and effectiveness are measured using qualitative and quantitative 
tests for eggs in faeces or urine. Cure rates and egg reduction rates are used to measure 
the response to treatment. These indicators are simple and easy to determine under field 
conditions. It is important to note that the qualityof results derived are dependent on the 
parasitological techniques used and on the time after treatment at which prevalence and 
intensity of infection are evaluated. 
PZQ has been associated with a cure rate of between 60-90% and sometimes egg reduction 
rate of up to 95% in different community- based studies. A complete cure of all study 
participants (100%) has not been achieved. In an endemic community in Nigeria, this 
author and colleagues have shown that the pre-treatment prevalence of S. haematobium of 
71% with microhaematuria and proteinuria of 83% and 94% respectively declined to 23%, 
27.5% and 19% respectively after two annual treatments with PZQ. As a result of the high 
cost of the drug and the labour intensive diagnostic methods involved, the authors 
recommended that chemotherapy should be given at yearly intervals to targeted school-
age children (Ejezie et al., 1998). The implication of this recommendation is that the money 
invested in diagnosis could be used in the procurement of more tablets of PZQ. In this 
same group of schoolchildren, the educational pass rate improved following the first 
treatment session from 81.4% to 90.7% but later declined to 84.2% following the second 
treatment session. The net improvement in school performance was statistically 
significant (X2 = 7.2; P= 0.027) (Meremikwu et al., 2000).To buttress their findings, the 
authors noted that the possibility of enhancement of educational performance as observed 
in the study should make regular, periodic treatment of children in communities with 
endemic schistosomiasis a more cost-effective and beneficial public health intervention 
strategy than was previously assumed. kabatereiene et al (2003) reported a cure rate of 
69% and egg reduction of 97-99% in individuals treated for S. haematobium infection in 
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Uganda. In a related study in Cameroon, a higher cure rate of 83-88.6% and egg reduction 
rate of 98% was reported following the administration of a standard dose of PZQ 
(Tchuente et al ., 2003). 
There are reports of disappointing cure rates with PZQ. In an area of intense S mansoni 
transmission in northern Senegal, PZQ administered at the standard dose gave a cure rate of 
18-36% (Gryseels et al., 1994). Subsequently, the dose was increased without any significant 
improvement in the efficacy rate (Guisse et al., 1997). However, when treated with 
oxamniquine, there was a significantly higher cure rate (Stelma et al., 1997). Relatedly, Ismail 
et al (1999) treated 1607 S. mansoni-infected patients in Egypt with PZQ at 40 mg /kg and, 
after an additional two treatments, the last at 60mg/kg, 1.6% of the patients were still 
passing viable eggs. It is remarkable that these low cure rates are more associated with S. 
mansoni than S. haematobium infection. 
In 2001, the World Health Assembly set a target of treating about 75% of schoolchildren 
infected with schistosomisis and soil-transmitted helminthes. This target is yet to be met. 
Available data showed that 18,151, 619 and 19,570,971 infected subjects were treated with 
PZQ in 2008 and 2009. Of this, 14, 498,101 subjects in Africa were treated. This statistics is 
based only on countries rendering treatment reports to WHO. Were all endemic countries to 
report, it is likely to be higher as more infected people now have access to PZQ and could 
afford treatment. Unlike in the 1980s and 1990s, PZQ is now cheap and affordable. The 
average price is about US$ 0.10/tablet or less (WHO, 2003). 
The availability of a dose pole which is based on height for the administration of PZQ is 
another innovation for the ease of community-based studies unlike the previous situation of 
measuring the weight of pupils. Weight measurement was limited by the sensitivity of the 
balance used which in some instances could lead to under or over dosing. Montresor et al 
(2001) reported on the validation of dose pole using existing data. This validation confirmed 
98.6% of school-age children would have received a PZQ dosage between 30 and 60 mg/kg 
body weight, and that 84.7% would have been between 40 and 60 mg/kg. Corresponding 
figures for the whole populations (including young children and adults) were 95.5% and 
68.2%. The validity of an extended PZQ dosing pole has been tested in Uganda (Sousa-
Figuriredo et al., 2010). The extended dose pole was found to be very accurate within 
Uganda as well as in Zanzibar (prevalence levels of acceptable dosages estimated were 
98.6% and 97.6%, respectively). It is thus considered to be a reliable and practical method for 
determining the dose of PZQ needed to treat schistosomiasis. 
3.1.4 Resistance of Schistosomes to PZQ 
Drug resistance is defined as “a genetically transmitted loss of susceptibility to a drug in a 
parasite population that was previously sensitive to the appropriate therapeutic dose” 
(WHO,1996). Currently, molecular biologic techniques are not available for the detection of 
resistance of schistosomes to PZQ. The resistance of Schistosomes to PZQ has recently been 
examined (Botros and Bennett, 2007). It cannot be scientifically ascertained whether cases 
not cured as encountered in the Senegalese and Egyptian studies were cases of resistance or 
drug tolerance. It has been noted that PZQ is partially immune dependent. Lack of acquired 
immunity in Northern Senegal where Schistosome infection was newly introduced may 
have perhaps accounted for the low cure rate. Remarkably, Fallon and Doenhoff (1994) were 
the first to point to a possible development of resistance as mice infected with S. mansoni 
were insensitive to PZQ. 
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In a related study, Fallon et al (1997) reported that a parasite line derived from an isolate 
from Senegal was less susceptible to PZQ than other isolates used as controls. Another 
supportive evidence can be deduced from the work of Ismail et al (1996). Several isolates 
were established in laboratory- maintained life cycles from eggs passed by uncured patients, 
and adult worms of these isolates were found to have PZQ ED 2- TO 5- fold higher after 
PZQ treatment in mice than isolates that had been established from eggs before treatment by 
patients who had been cured. 
PZQ is known to kill the adult worms and not the immature stages. It is possible that the 
uncured subjects were harbouring the immature stages of the parasite at the point of 
treatment. As a follow up to this, a protocol was suggested for screening for suspected 
instances of PZQ resistance; this consisted of administering two doses of the drug, 2-3 weeks 
apart, so that the second would eliminate any schistosomes that had matured in the interval 
(Renganathan and Cioli, 2000). The utilization of this protocol in Northern Senegal achieved 
the expected higher cure rates (Picquet et al.,1998). 
The issue of schistosome susceptibility or resistance to PZQ is further confounded by the 
fact that PZQ failed to cure a schistosome infection that was acquired by travelers or 
military personnel in endemic countries after returning to their non-endemic country of 
origin (Silva et al., 2005). 
It is difficult to dismiss the high rate of uncured subjects in Senegal which were 
subsequently cured upon the administration of Oxamniquine as not being due to 
resistance. However, in the absence of a clear scientific tool to detect resistance, there is 
need for vigorous monitoring of the efficacy of PZQ as it remains a drug of choice for the 
treatment of schistosome infection in the foreseeable future. Additionally, there is a 
consensus of opinion that drug manufacturers and researchers should commence a 
sustained search for an alternative drug to PZQ. Ro 15-5458 is one of such candidate 
compound discovered about 20 years ago by Hoffman-La Roche (Basel, Switzerland). 
Administered, at a single dose, it was highly efficacious against both the immature and 
adult worms (Sulaiman et al., 1989; Pereira et al., 1995). Another prospective candidate 
compound is 2-(alkylamino)-1-phenyl-1-ethanethiosulfuric acid. It has been attributed 
with the elimination of a very high population of female schistosomes than male worms 
in a mouse model. A lot of studies are required before it can be used for the treatment of 
infected human subjects (Moreira et al., 2007).  
3.2 Oxamniquine 
3.2.1 Molecular structure and pharmacokinetics 
Oxamniquine was first described in the late 1960s. The compound is 6-hydromethyl-2-
isopropyl-aminomethyl-7-nitro 1,2,4-tetrahydroquinoline. It is produced by biological 
processes. The drug is administered as 15mg/kg body weight for adults while children are 
treated with 20mg/kg given in two doses of 10mg/kg each in an interval of 3-8 hours. It is 
extensively metabolised through oxidation process. The metabolites are active and excreted 
in urine. The side effects are mild, transient and well tolerated especially when given after a 
meal (Utizinger et al., 2003). 
3.2.2 Mode of action 
Unlike PZQ, the mechanism of action of oxamniquine is fairly well understood. 
Oxamniquine is only active against S. mansoni but not effective against S. haematobium and S. 
www.intechopen.com
 Schistosomiasis 
 
80
japonicum. The active ingredient is tetrahydroquinoline which acts on the adult S. mansoni 
and immature invasive stages, with males more susceptible than the females. Its 
anticholinergic effect, which increases parasite motility and inhibits nucleic acid synthesis, 
has no notable effect on the other Schistosome species (Secor & Colley, 2005). The mechanism 
of action of oxamniquine is related to irreversible inhibition of nucleic acid metabolism of 
the parasite. The drug is activated in a single step, in which the Schistosoma enzyme converts 
the oxamniquine to an ester, and spontaneously dissociates resulting in an electrophilic 
reactant and alkylation of the Schistosoma DNA. Worm death is associated with the 
formation of sub-tegumental vesicules in adult parasites. Different responses are observed 
after therapy, with less specific morphological alteration and hepatic shifts, occurring over a 
period of six days post treatment (Utzinger et al., 2003). 
3.2.3 Application of oxamniquine in S. mansoni control programmes 
Oxamniquine is not used widely for the control of S. mansoni infection particularly in 
Africa because it is more expensive than PZQ. The fact that it proved more effective than 
PZQ in an endemic focus in Northern Senegal where PZQ gave an embarrassing low cure 
rate still recommends its usage. However, the drug is widely used in Brazil and other 
South American Countries for the control of S. mansoni infection. Katz and Coelho (2008) 
reported that over 12 million doses of the drug were administered in a control programme 
in Brazil alone. 
3.3 Metrifonate 
Metrifonate was initially introduced as an insecticide in 1952, but later in 1960, it was used 
to treat helminth infection. The drug also refer to as trichlorophone is a cheap 
organophosphorus ester which is only active against S.haematobium. It is rapidly absorbed, 
metabolized and excreted. The metabolic pathway yields DDVP (2,2-dichlorovinyl 
dimethylphosphate), a cholin esterase inhibitor which is the active compound. The 
mechanism of action is not known. It is relatively cheap and is not toxic. Metrifonate is 
administered as 7.5-10 mg/kg body weight, given in three divided doses in two weeks 
interval. Among the side effects reported following the administration of the drug include 
abdominal pains, diarrhoea, fatigue and muscular weakness which dissipates within 12 -24 
hours (Danso-Appiah et al., 2008). The reasoning behind the widely spread dosage has to do 
with its inhibitory effects on red cells and plasma cholinesterase. 
Metrifonate is not used currently for the treatment of urinary schistosomiasis. Several 
reasons account for this. One of which is poor compliance by patients as a result of the 
spacing and multiple dosing. The second reason is reduced level of efficacy. For instance, 
Mgeni et al (1990) reported a cure rate of 40% and egg reduction rate of 90% in Zanzibar. 
Lastly the advent of PZQ with its superior efficacy rate and broad spectrum activity meant 
that it was no longer cost effective and sustainable to rely on metrifonate. 
3.4 Artemisinin and its derivatives 
3.4.1 Biochemical characteristics and pharmacokinetics 
The artemisinins though syntheised for the treatment of malaria is the newest drug used 
for the treatment of schistosomiasis. Unlike PZQ, which is active against the adult stages 
of the parasite, artemisinin is active against the immature stage of parasite. It is a 
sequitterpene lactone with a peroxide group, obtained from the leaves of the plant, 
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Artemisia annua which are grown in Central Europe, China, USA and Argentina among 
others. The major derivatives of artemisinin are artesunate, artemether, arteether with 
dihydroartemisinin as the principal active metabolite. Primarily they are antimalarials, 
but the anti-schistosomal properties were discovered by Chinese scientists in the 1980s 
especially for the treatment of S japonicum infection (Hommel, 2008). They are well 
tolerated with only minor side effects. 
3.4.2 Mode of action of Artemisinin 
The precise mode of action of this drug is not known. Artemether is the most potent. It 
exhibits the highest level of activity on one to three weeks old liver stages of the parasite. 
When a dosage of 6mg/kg weight is administered, it kills the schistosomulas during the 
first 21 days. The invasive and adult stages are less affected and the adult females are more 
susceptible than the males (Allen et al., 2002). Following treatment, artemether induces 
severe and extensive tegumental damage and significant reduction in glycogen contents 
through the inhibition of glycolsis, but the onset of this alteration is slow. It also hinders the 
development of egg laying adult worm pairs (Xiao et al., 2000). 
3.4.3 Efficacy of artemisinin in field studies 
Several studies have been carried out to test the feasibility of using artemisinin for the 
treatment of schistosome infection. The efficacy of oral artemether for prevention of S 
mansoni infection was investigated in Western Cote d’Ivore (Utzinger et al., 2000). The group 
that received artemether had a significantly lower incidence of S mansoni infection (31/128 
versus 68/140, relative risk: 0.50 [95% CI 0.35-0.71], P=0.00006). The geometric mean egg 
output among positive children in the artemether group was significantly lower than in the 
placebo group (19 vs 32 eggs/g stool, p=0.017). The authors recommended the use of 
artemether in an appropriate situation as an additional tool for the control of intestinal 
schistosomiasis. In the same country, the activity of artemether against S haematobium 
infection has also been assessed. The incidence of patent S. haematobium infections in 
artemether recipients was significantly lower than in the placebo recipients (49% vs 65%, 
protective efficacy: 0.25, 95% CI: 0.08-0.38, P=0.007). The geometric mean intensity in the 
artemether group was less than half that of the placebo recipients (3.4 versus 7.4 eggs/10ml 
urine, P<0.001). Heavy S. haematobium infections, microhaematuria and macrohamaturia, 
and the incidence of malaria parasitemia were all significantly lower in artemether patients. 
The authors concluded that artemether was active against S haematobium (N’Goran et al., 
2003). Boulanger et al (2007) have also associated artesunate combination therapies with 
high cure rate of S. haematobium infection in Senegal. This author and colleagues 
investigated the efficacy of artesunate in the treatment of urinary schistosomiasis in Nigeria 
(Inyang-Etoh et al., 2004)(Table 2). When the treated children were re-examined 4 weeks 
after the second dose of artesunate, 70.1% appeared egg- negative and were therefore 
considered cured. Post-treatment, the geometric mean egg count for the treated subjects 
who were not cured was significantly lower than the pre-treatment geometric mean egg 
count for all the treated subjects, with log10[(eggs/10 ml urine) +1] values of 0.9 versus 1.75 
(t=4.45; P<0.05). The artesunate was well tolerated. The authors concluded that their 
observation of a therapeutic effect of artesunate against S. haematobium infection in Nigeria 
confirmed recent observations from Senegal. Furthermore, it would be more cost effective to 
treat S. haematobium infection in this setting with artesunate than with PZQ. 
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 Males Females All X2 P 
Subjects Aged <10years      
No. Treated 11 21 32 NA NA 
No. and (%) cured 7(64) 15(71) 22(69) 0.2 >0.05 
No and (%) without post-treatment 
haematuria 
10(90) 18(86) 28(88) 1.66 >0.05 
No and (%) with post-treatment 
haematuria 
1(9) 3(14) 4(13) 0.09 >0.05 
Subjects Aged>10 years      
No Treated 31 24 55 NA NA 
No and (%) cured 20(65) 19(79) 39(71) 1.40 >0.05 
No and (%) without post-treatment 
haematuria 
23(74) 20(83) 43(78) 0.65 >0.05 
No and (%) with post-treatment 
haematuria 
8(26) 4(17) 12(22) 0.66 >0.05 
NA, Not Applicable 
(Adopted from Inyang-Etoh, Ejezie, Useh et al.,2004) 
Table 2. The prevalences of haematuria post-treatment with artesunate and the frequencies 
of parasitological cure, split by age and gender. 
Researchers have administered a combination of PZQ and artesunate on schistosomiasis 
infected subjects in a bid to derive a synergistic effect. While PZQ acts on the adult worms, 
artesunate acts on the immature stages of the worm. Borrmann et al (2001) investigated the 
efficacy and tolerability of artesunate, singly or in combination with PZQ, for the treatment 
of S. haematobium infections among 300 schoolchildren in Gabon. Of the children given PZQ 
+ placebo, artesunate + placebo, artesunate + PZQ and placebo alone, 73%, 27%, 81% and 
20% appeared cured, respectively. In summary, earlier findings of efficacy of artemisinin 
derivatives against S. mansoni and S, japonicum could not be confirmed against S. 
haematobium in the endemic focus. In a related study, conducted in two villages endemic for 
S. haematobium infection in Senegal, De Clercq et al (2002) reported that treatment with 
aretesunate alone gave egg count reduction rates that were high and almost as good as those 
obtained with PZQ ( though the results obtained with PZQ were consistently better). 
Inyang-Etoh et al (2009) assessed the efficacy of a combination of PZQ and artesunate in the 
treatment of urinary schistosomiasis in Nigeria (Table 3). All treatment regimens were well 
tolerated. The cure rates were 72.7% in the PZQ plus placebo treated group and 70.5% in the 
artesunate plus placebo group, while the artesunate plus PZQ group had the highest cure 
rate (88.6%). The authors concluded that the treatment of urinary schistosomiasis with a 
combination of PZQ and artesunate is safe and more effective than treatment with either 
drug alone. The authors were however silent about the element of cost of the combination 
therapy. It is more expensive to use the combination than using either singly. The element of 
cost is very crucial in the choice of the appropriate drug to use as it should be affordable by 
the rural poor who are often afflicted by the disease.  
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Effect of treatment PZQ Plus 
placebo 
(n=44) 
Art Plus 
placebo 
(n=44) 
Art plus 
PZQ 
(N=44) 
PZQ without 
placebo 
(n=42) 
Art without 
placebo 
(n=44) 
Placebo 
plus 
placebo 
No (%) cured 32(72.7) 31(70.5) 39(88.6) 31(73.8) 33(75) 4(9.1) 
Mean ova reduction 
rate 
79.3 72.3 93.6 76.7 52.1 111.5 
Mean ova count 
before treatment ±SD 
66.3±3.7 69.6±2.7 62.2±2.1 42.0±1.7 39.8±1.1 34.1±0.8 
Mean ova count after 
treatment±SD 
13.8±0.8 19.3±0.9 4.0±15.2 9.8±0.5 19.1±1.0 72±2.3 
Mean haematuria 
before treatment ±SD 
55.9±2.0 50.9±1.9 73.0±2.3 47.6±2.0 61.8±2.2 38.0±1.6 
Mean haematuria after 
treatment ±SD  
13.6±1.2 11.1±0.9 8.8±8.7 7.6±0.9 25.7±1.6 59.6±2.2 
Mean Proteinuria 
before treatment±SD 
190.9± 177.3±5.1 267.5±5.4 160.2±5.2 191.1±5.2 185.2±5.0 
Mean Proteinuria after 
treatment±SD 
65.7±3.3 85.5±3.9 4.0±15.2 24.8±1.9 102.1±4.4 213.9±5.3 
(PZQ denotes Praziquantel, Art denotes Artesunate) 
Source: Inyang-Etoh, Ejezie, Useh et al., 2009) etc 
Table 3. Summary of therapeutic efficacy of PZQ and artesunate administered with placebo 
or in combination in Nigeria. 
Artemisinins were originally snythesised for the treatment of malaria. There is a 
likelihood of a build up of resistance in malaria endemic areas where the drug is equally 
used in the treatment of schistosomiasis. It is worth noting that the combination therapy 
as it were has not given 100% efficacy so far in field studies. This is crucial as all the stages 
(immature stages and adult) of the parasite are targeted by the two drugs. This brings the 
issue of resistance once again to the fore. It might not be unreasonable to assume that the 
residuals not responding to the combination therapy might be pointing to a certain level 
of resistance. This would also imply that we be circumspect in deploying artesunate to 
treat schistosomiasis in areas endemic for malaria since it may enhance the development 
of resistance. 
4. Mollusciciding in schistosomiasis control 
In the early days of schistosomiasis control in Egypt, a lot of emphasis was placed on 
molluciciding in a bid to interrupt transmission. Although, it is a component of an 
integrated method of control, it is not used currently in many endemic areas. Rather 
morbidity control in the short term using chemotherapy is more emphasized. Snail control is 
achieved by using chemical and plant molluscicides, biological predators and ecological 
methods. The main objectives of the use of molluscicides is to contribute, preferably in 
combination with chemotherapy and other feasible control measures, to significant 
reduction/control of schistosome transmission by cost-effective destruction of snail host 
populations and in particular, infected snails in selected habitats. The snail population 
density at transmission sites should be reduced by 95% (WHO, 1992). 
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The advantages to be derived from mollusciciding are: 
1. Rapid interruption of transmission 
2. Satisfactory cost efficiency 
3. Non-desirability of community participation and utilization of simple application tools 
4. Guaranteed safety margins to man and his domestic animals and plants 
5. Easy integration with other pesticide control programme 
The disadvantages to be derived include the following 
1. The need for repeated applications, since eradication of snail host populations is rarely 
attainable 
2. Requirement of technical discernment 
3. Effect on schistosomal morbidity, even when snail control measures are efficient and in 
the absence of chemotherapy is delayed (WHO, 1992). 
4.1 Qualities of a good molluscicide 
There is currently no perfect molluscicide. It is not easy to develop a molluscicide that is 
likely to offer all the advantages outlined above. However, the basic requirements have been 
laid out by the WHO (1965). These include the following: 
1. Toxicity to snails at low concentration 
2. They must be safe to use in respect of acute and chronic mammalian toxicity 
3. If they enter the food chain, they must not produce adverse effects 
4. They must be stable in storage for 18 months or longer 
5. Acceptable cost and ready availability 
6. Particularly specific for snails 
7. Low toxicity for non-biota 
8. Diversity of formulations 
9. Simple means of application and reliable means of measuring concentration in habitat 
4.2 Assessment of effectiveness of some chemical molluscicides 
A variety of compounds are molluscicidal. Among these include; penta chlorophenate, 
calcium, copper, lead and tin compounds which have been discarded because of toxicity. 
The molluscicidal property of copper, irrespective of the method of application has been less 
than satisfactory, especially in the presence of organic materials, certain kinds of dissolved 
solids, and at high PH values. Moreover, the cost effectiveness for copper sulphate, inspite 
of its low price, has been shown to be unacceptably high in comparison with that of 
niclosamide (McCullough, 1992). 
4.2.1 Mode of action of some chemical molluscicides 
Poisoning with molluscicides causes the snail either to retract into the shell and expel the 
haemolymph or to become swollen and remain extended from the shell. The later response 
is seen particularly with organotins and certain carbamates and suggests lost of water 
balance control (WHO, 1992). The water balance of gastropods is thought to be under 
neurosecretory control. N-tritymorpholine has been shown to reduce neurosecrtory control 
in B. truncatus, while long term exposure of the pulmonate, Indoplanorbis exustus, to barium 
chloride and copper sulphate also resulted in diminished neurosecretory activity. In 
addition, it has been shown that water flux through B. glabrata falls in the presence of a 
number of molluscicides at concentrations around their LC 50 values (McCullough, 1992). It 
may well be, therefore that molluscicides cause stress on the water-balance system and that 
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this alone is lethal to the snail, or that reduction of the normal water flow through the snail 
precipitates other functions similar to those describe above. 
4.2.2 Effectiveness of some chemical molluscicides 
In Japan, an inexpensive compound named B-2 (Sodium 2,5 dichloro-4-bromophenol) has 
been field tested in liquid and wettable powder formulations against the amphibious 
Oncomelania nosophora (Kajihara et al., 1979). Its residual concentration in soil decreased 
rapidly and its uptake in rice did not exceed 0.03 mg/L. Its toxicity has limited its wide 
spread use. The properties of some chemical molluscicides is presented on Table 4. 
Niclosamide (marketed as bayluscide) is virtually the sole available molluscicide and in 
terms of effectiveness and completeness of evaluation. It is the molluscicide of choice 
(WHO, 1992). It has been a commercial success. The usual formulation of bayuscide (70% 
wettable powder and 25% emulsifiable concentrate) are both highly effective. In practical 
use, a concentration of 0.6-1 mg/L is recommended with exposure time of 8 hr (WHO, 1973) 
or 0.33 mg/L for 24 hr (Barnish and Prentice, 1981). Currently, there is no proven resistance 
to bayluscide. In a recent study, Dai et al (2010) showed that a novel suspension concentrate 
of niclosamide was toxic against B. glabrata. There was no differences in the effect of the 
suspension concentrate, the wettable powder of niclosamide and the ball-milled pure 
niclosamide against the adult snail. 
The distribution of the snail hosts in their habitat is non-random, reflecting the where about 
of the food resources ( e.g decaying vegetation, algae) and also physical features (e.g 
sandy/muddy substratum, water flow patterns) which attracts or repulse the mollusks 
(WHO, 1985). Snail host populations thus tend to be dynamic in space and time. These 
principles and the observations that low infection rates (e.g less than 1%) in snails may be 
associated with relatively high infection rates in a local community point to the need to 
identify potential transmission sites both geographically and seasonally, and to predict the 
 
Physical 
properties 
Niclosamide Copper Sulphate Sodium Penta 
Chlorophenat 
Nicotinanilidae 
Candidate 
compound Group 
Form of Technical 
material 
Crystalline Solid Crystalline solid Crystalline Solid Crystalline Solid 
Solubility in 
Water 
230mg/L PH 
Dependent 
316g/L 330g/L Not known 
Toxicity     
Snail, LC 90 3-8 20-100 20-100 5 
(mg/L x h) 2-4 50-100 3-300 20-50 
Cercaria LC 90     
Formulations 700g/kg wetteble 
powder, 
250/ml/L 
emulsion 
concentration 
980g/kg 
pentahudrate 
crystals 
750g/kg flaks 
800g/kg pellets 
800g/kg 
triquettes 
Not yet 
formulated 
Source: WHO (1973) 
Table 4. Properties of Some Available and Candidate Molluscicides 
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habitats favoured by the snails (Anderson & May, 1979). Klumpp and Chu (1987) stated 
that in their experience in Iran, Egypt and Ghana, area wide mollusciciding was 
expensive, wasteful, ecologically unsound and generally ineffective. They concluded on 
the other hand that focal mollusciciding is a cost effective method in virtually all habitats. 
However, in endemic areas like the Nile Delta, it is unlikely that even focal/seasonal 
mollusciciding will contribute significantly to a reduction in schistosomal transmission in 
the area as a whole. However, in certain affected communities where for example, 
population-based chemotherapy campaigns may have proved less satisfactory, 
focal/seasonal mollusciciding, if carried out rigorously could probably play a useful, 
additional role in disease control. 
The efficiency of focal molluscicide treatment against schistosomiasis re-infection in an 
irrigation scheme and in small dams area in Mali has been undertaken (Werler, 1989). The 
cost factor alone was sufficient to reject focal molluscicide treatment especially at the 
Plateau Dagon since transmission starts at the end of the rainy season if there is still water 
in the dams by then and slows down in the cool dry season. Laboratory evaluation of B-2 
in the control of the snail intermediate host of schistosomiasis in South Africa has been 
conducted (Joubert and Precious, 1991). The authors noted that though B-2 has a marked 
potential for snail control in South Africa, that niclosamide remains the molluscicides of 
choice. 
There are a lot of problems mitigating against the application of chemical molluscicides 
particularly in sub-Saharan Africa. It is not likely that community participation would be 
guaranteed for the purpose of focal mollusciciding in endemic areas. The other problems are 
high illiteracy rate and cost of procurement of molluscicides.  
4.3 Plant molluscicides 
During the last two decades several excellent reviews on plant molluscicides have been 
published (Kloss and McCullough, 1982; Mott, 1987). Some major classes of natural products 
with recognized molluscicidal activity is presented on Table 5. 
In several African countries, plant molluscicides have been identified and tested as a 
component part of an integrated control programme. Mkoji et al (1989) evaluated the 
molluscicidal activity of Solanum aculeatum berries against Biomphalaria pfeifferi, Bulinus 
globosus and Lymnea natalensis in Kenya. Fifty (50) mg powder L-1 of sun freeze-dried berries 
killed over 60% of all the tested snails while 25mg L of the sun dried material killed less than 
60% of the test snails whereas similar concentrations of the freeze dried molluscicides 
produced 60-80% mortality in the snails under similar conditions. These findings suggest 
that S. aculeatum is a potent molluscicide and has the potential for the control of vectors of 
schistosomiasis and fascioliasis in Kenya. In Egypt, the molluscicidal properties of Ambrosia 
maritina on schistosome snail intermediate host has been assessed. This study was combined 
with the administration of PZQ. The authors concluded that A. maritina offers an alternative 
community participation approach whereby farmers could grow and apply the plant for 
themselves so that an area of any size could be treated in a short period of time. A maritina 
was able to reduce populations of Biomphalaria alexandrina significantly (Elsawy et al., 1989). 
Latex from the plant Euphorbia splendens var hislopi, also known as ‘Crown of Christ’ have 
been discovered to have molluscicidal effect on snails of the genus Bulinus and Biomphalaria. 
Schall et al (1998), obtained a 90% lethal impact on egg masses and embryos of these snails. 
This is one of the most potent molluscicides. 
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Class of Compoud Plant Family 
Triterpenoid Saponins Phytolacea Dodecandra Phytolaccacee 
 Hedra helix Araliaceace 
 Lonicera nigra Caprifoliaceace 
Spirostanol Saponins Cornus florids Cornaceace 
 Balanites aegytiaca Balaniotaceae 
 Asparagus curillus Liliaceae 
Steroid glycoalkaloids Solanum mammosum Solanaceae 
Diterpenes Wedelia scaberrima Compositae 
 Baccharis trimera Compositae 
Sesquiterpenes Warburgia ugandensis Canellaceae 
 Warburgia stuhlmannii Canellaceae 
 Ambrosia maritime Compositae 
 Podachaenium eminens Compositae 
Monoterpenes Genus Lippia Verbenaceae 
Iridoids Olea europaea Oleaceae 
Naphthoquinones Diospyres usambarensis Ebenaceae 
Alkenyl phenols Anacardium occidentale Anacardiaceae 
Chalcones Polygonum senegalense Polygonaceae 
Flavonoids Baccharis trimera Compositae 
Tannins Acacia nilotica Leguminosae 
(Adopted from Marton and Hostettman, 1985) 
Table 5. Major Classes of Natural Products with Recognised Molluscicides Activity 
A major issue in the utilization of plants molluscicides is the acceptance and ownership of 
the initiative by community members. In the absence of this, cultural and religious factors 
may interplay negatively to hinder control. Community acceptance has been tested by 
different researchers in different settings. The processing and application of the soap berry 
plant (Phytolacca dodecandra) was tested in Ethiopia, where the plant is known as endod. Both 
occasional spraying and the use of endod soap for washing clothes were tested and it 
appeared that spraying would be the least labour- intensive method of control in that 
setting. Ndamba et al (1989) in a related study in Zimbabwe examined the knowledge, 
attitude and practice of the locals on both schistosomiasis and the soap berry plant. A large 
number of the participants accepted that schistosomiasis was a problem but none of them 
knew the role of snails in the transmission of infection. Although, they did not previously 
know of the plant as a molluscicides, a higher proportion of the people were willing to grow 
the plant after a brief explanation of it use. 
It appears morbidity control of schistosomiasis anchored chiefly on population based 
chemotherapy has taken the centre stage in the organization of schistosomiasis control even 
with the acceptance of an integrated approach to control. The vigor thrown in by researchers 
in the early 1970s to 1990s in the search and evaluation of plant molluscicides has not been 
sustained. 
4.4 Utilisation of competitor snails 
Another approach to the elimination of snail hosts of schistosomiasis is the introduction of 
competitor snails in the habitat to the prey on the former. The South American snail, Marisa 
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cornuarieta is a noted prey of B. glabrata and this has been demonstrated in Puerto Rico 
(Muller, 1975). Similarly, the fresh water fish, Astateodromes is known to prey on mollusks. 
The Planorbid snail, Helisoma duryi, originally endemic in Florida, USA has been suggested 
as a biological competitor against the intermediate host snails of schistosomiasis. During the 
past three decades researchers have speculated on the possibility of using this particular 
snail as a biocontrol agent. Althought the results of some experiments indicated that H. duryi 
could control certain intermediate hosts under laboratory conditions and semi natural 
environment (Madsen, 1981), a number of field trials were either inconclusive or 
unsuccessful (Jordan, 1985). 
Pointer et al (1989) have reported on the use of the parthenogenetic snails, Thiara granifera 
and T. (Melanoides) tuberculara to eliminate the intermediate host of S mansoni- B. glabrata in 
the Carribean area. These oriental snails are noted for their capacity to colonise rapidly and 
densely, many types of habitats while at the same time reducing and even eliminating 
populations of Biomphalaria Spp. In St Lucia, B glabrata was apparently eliminated from 
marshes and streams, 6 to 2 months after the introduction of the competitor. In Martinique, 
T tuberculata was introduced and in just less than 3 years, both B. glabrata and B. straminea 
were eliminated from the transmission sites. They concluded that, the Thiarid snails as 
competitors of pulmonates are favoured by the presence of permanent and stable habitat, 
preferably shallow, with emergent plants. 
Taken alongside other measures, such as mollusciciding and chemotherapy, the goal of 
eradication of schistosomiasis appears feasible and attainable in the long run. But some 
posers remain. What would likely be the long term impact between the interaction of 
schistosomes and competitor snails? Would they become vectors themselves someday? The 
utilization of this method would remain as a research tool for sometimes. 
5. Ecological modification 
Habitats can be made unsuitable for snails to exist by alternate flooding and drying of water 
channels, covering and lining of canals and filling in of marshy areas. Though these 
methods are likely to be permanently successful, they are expensive. Chenq (1971) reported 
that in Kiagsu and Chekiang provinces of China, the 10.5 million cases of schistosomiasis 
estimated to be present by 1955 were claimed to have been reduced by one third using 
ecological procedures in combination with the storage of night soil before use on the land 
and a three day treatment campaign with tartar emetic. The reduction in the water level, 
including complete drainage of the habitat, resulted in the death of the snails through 
desiccation (Boelee & Laamrani, 2004). Similarly, the ecological benefits to the snails such as, 
the presence of algae which served as their main source of food are removed. The lining of 
the canals with cement is another measure that may be adopted. It reduces the accumulation 
of silt and the growth of the vegetation; this in turn reduces the snail population at the site. 
Local participation is known to ensure the sustainability of this approach. In Morocco, the 
cost of control was reduced while the people took responsibility for their environment and 
health (Boelee & Laamrani, 2004). Strickland (1982) noted that such environmental 
management led to improved agricultural productivity in endemic areas. 
5.1 Modification of the water-related activities of residents of an endemic area 
Several studies have confirmed a strong link between the water related activities of residents 
of schistosome endemic communities and the prevalence and intensity of infection. In 
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Nigeria, Useh & Ejezie (1999b) showed that intensity of infection was more closely 
correlated with the number of water contacts (r=0.97) than with the total duration of 
exposure (r=0.77), emphasizing the importance of specific/multiple activities, and of the 
surface area of the body submerged in transmission. Although, the authors investigated four 
fresh water streams, one of them (Culvet) was identified as the main transmission point, 
with bathing/swimming and fishing as the main activities that predisposed people to 
infection (see Table 6). 
 
Age 
(years) 
No of 
Observa
tions 
No of  
Contacts 
Mean No of 
Contacts/pers
on-day 
Total 
Duratio
n 
(min) 
Mean 
Duration/
Contact 
.day (min) 
No and (%) 
of 
Subjects 
infected 
5-9 479 489 1.20 4328 8.85 265(55.32) 
10-14 559 588 1.05 6831 11.62 402(71.91) 
15-19 385 442 1.15 7622 17.24 230(59.74) 
20-24 298 318 1.07 7273 22.87 114(38.25) 
25-29 172 188 1.09 5153 27.41 36(20.93) 
30-39 158 162 1.03 4923 30.39 21(13.29) 
>40 85 87 1.02 1095 12.59 8(9.41) 
All 2136 2274 1.07 37225 16.37 1076(50.37) 
(Adopted from Useh & Ejezie, 1999b) 
Table 6. Frequency of water contacts, duration of exposure and prevalence of infection, by 
age of subjects 
The application of the results of a study like this may change the attitude of the residents by 
encouraging them to avoid activities that expose them to infection. In a Zimbabwe study, 
Chandiwana and Woolhouse (1991) showed that water contact rates were related to age 
(highest in 8-10 years old) but not sex, with substantial variation unaccounted for by these 
variables. Their results provide strong quantitative support for control programmes aimed 
at heavily infected sites (eg focal mollusciciding) or at the minority of individuals making 
most water contact (e.g targeted chemotherapy). 
The creation of habitats for intermediate hosts of many parasitic diseases including 
schistosomiasis can be avoided if there is collaboration by Government Departments 
charged with the supervision of building dams for agricultural purposes and hydro-electric 
power resources for energy supply. In the absence of this and proper channeling of canals, 
the government and the residents of such disease endemic areas would need any or 
combinations of the options outlined above to control the disease in question. The WHO 
(2000) defined three principles that are fundamental in dealing with the association between 
water resources development and human health: 
- Equity. The benefits of water resources development are not disputed, but the uneven 
distribution of benefits (including health benefits) and of health risks to vulnerable groups, 
needs to be addressed in the planning, construction, and operation of such projects 
- Economics. Negative health impacts of water resources development represent a 
hidden cost to the health sector whose resources are, as a rule, already over-stretched 
- Sustainability. The economic return from investment in water resources development 
will suffer substantially from the ill health of local communities, with no sustainability 
at all in extreme case where dramatic health impacts force people to move away. 
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Where these principles are taken into consideration and actually put into practice water 
resources development would not create avenues for infection thereby sustaining the cycle 
of poverty and disease. 
6. Sanitation and water supply 
At the global level, the disability-adjusted life years (DALYs) from insufficient water, 
sanitation and hygiene (including contact with schistosome-infested waters) suggested that 
4% of all deaths and 5.7% of the total disease burden can be attributed to these largely 
preventable conditions. However, with the emphasis placed on morbidity control of 
schistosomiasis using population-based chemotherapy, there is less focus on interventions 
related to safe water supply and sanitation, which in theory could contribute to controlling 
transmission of all helminths and many other infections (Prus et al., 2002). Bruun & Aagaard 
(2008) noted that the establishment of safe and adequate water supply and sanitation 
facilities at household and village levels has an effect on domestic utilization patterns, but 
the relationship to prevalence of schistosomiasis remain complex. 
6.1 Sanitation 
Sanitation is often considered as too expensive, but it is not known what proportion it 
would make up compared with sums spent on classical measures for the control of 
schistosomiasis. Schistosomiasis is transmitted through the contamination of water bodies 
with the eggs of the parasite via stool or urine. Considering the high reproductive 
potentials of the parasite, a single miracidium produces thousand of cercariae, thus a 
small proportion of human waste containing parasite eggs, reaching snail infested water 
is sufficient to maintain effective transmission in an area (Hotez et al., 2006). The 
provision of latrine facilities does not imply that they are always used by everybody as 
intended (Asaolu & Ofoezie, 2003). In a Brazilian town, where facilities were limited, 
Kvale (1981) showed that there was no significant difference in prevalence between 
people from households with septic tanks and people from households without such 
facilities. In a recent study in Brazil, Andrade et al (2009) showed that improved sanitation 
and income are associated with decreased rates of hospitalization for diarrhoea in infants. 
In a related study in Eygpt, el Katsha & Watt, (1997) showed that overall infection levels 
were higher in the village without a sewage system. When measured at household level, 
there was a statistical significant relationship between infection levels and the absence of 
sewerage connections, but in the better drained village, there was no similar significant 
correlation. Eventhough only a third of households were connected to the sewerage 
system in this village, the system had contributed to lowering the water table to the 
benefit of the general village environment. 
Quite often sanitation is viewed and accepted as being very expensive. It has tremendous 
benefits not only in helping to control schistosomiasis but other endemic tropical diseases 
particularly those associated with fecal-oral route of transmission. When sanitation is 
accepted as the traditional way of life, the issue of cost would be grossly reduced. The 
Governments of endemic areas have the responsibility of the provision of sustained safe 
disposal of waste and the provision of simple public toilets. What is needed is to educate the 
people to desist from using faeces as fertilizer and enlightenment on their other actions 
which may predisposed them to infection 
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6.2 Water supply 
The provision of alternative sources of safe water, such as piped water, wells, water tanks 
and laundry areas for domestic and recreational uses, contributed to effective reduction in 
the rate of transmission and re-infection (Kloos et al., 2008). As an experimental control 
measure to reduce the transmission of S. mansoni, an individual household water supply 
was provided in 400 houses in 5 rural settlements of the Riche Fond Valley, St Lucia (Jordan 
et al., 1975). This population of about 2000 had previously been dependent for water on 
infected streams and rivers. Six other settlements in the valley, all provided with limited 
piped water from public standpipes, served as comparison area. After 2 years the incidence, 
prevalence and intensity of infection with S. mansoni were significantly lower in the 
household water supply area, whereas all these indices of infection had increased in the 
comparison area. The authors concluded that an adequate, reliable, and convenient supply 
of water can reduce the transmission of S. mansoni and should be considered as a control 
measure in other endemic areas. A comprehensive water delivery system consisting of a 
water outlet to each house, communal laundries, shower facilities, and play pools, coupled 
with health education were studied to determine the role they could play in the spread of 
schistosomiasis in St Lucia, West Indies (Jordan, 1988). After a 4 year period, the incidence 
of new S mansoni infections among children aged 2-5 years fell from 19.3% to 4.5% while 
over the same period in villages served by a standpipe system the incidence fell only slightly 
from 16.5%- 14%. In a related study in Cameroon, Ndamkou and Ratard (1990) investigated 
the role of sanitation, water supply and a health centre in the control of schistosomiasis. The 
authors noted that these parameters were effective in reducing the prevalence of 
schistosomiasis infection. In a different focus in Cameroon, Tchuem et al (2001) studied the 
impact of installation of a water pump on schistosomiasis transmission. They concluded that 
schistosomiasis focus evolve dynamically, and demonstrated that changes in water supply, 
in association with other actions such as repeated chemotherapy, may have a profound 
effect on disease transmission. A study in Kenya that installed community standpipes and a 
shower unit at the local school observed that the new water sources had a great influence on 
some villagers water contact behaviour and very little on the rest of the villagers (Noda et 
al., 1997). El Kholy et al (1989) investigated the effects of borehole wells on water use in a 
high prevalence area in Kenya, which showed no short-term effect on the transmission of S. 
haematobium, but a significant number of households changed to borehole water for 
drinking, cooking and dish washing. 
A clean source of water would limit the possibility of contacting parasitic, virial and 
bacterial diseases. Although the importance of this is realized in the Developing world, the 
governments lack the financial and political will to embark on this. Where borehole water is 
provided, no mechanism is often in place for the maintenance of the facility. When it mal-
functions, the residents resort to infested water bodies and become infected and the cycle of 
infection continues. There is also the need to take care of the recreational needs of the 
residents where piped water is available. 
7. Health education 
Health education is recommended as the entry point for initiating a control programme. 
Health education is that “aspect of health care directed towards promoting and reinforcing 
healthy behaviour through full participation of the individuals and communities 
concerned”. It is a voluntary process that encourages people to make informed decisions to 
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improve and maintain their health (WHO, 1990). A systematical approach is required in 
order to properly educate the residents of schistosomiasis endemic areas to buy into the 
project. This is achieved through health educational planning which has the ten under listed 
components: 
- A title 
- A description of the target population, 
- A statement of the problem or need 
- A list of programme and educational objective 
- A description of the means for community involvement 
- An analysis of the factors that will promote or hinder programme success 
- A list of appropriate health education strategies 
- An outline of the resources available and the need for the programme 
- A timetable for action 
- A scheme for evaluation 
A programme executed after the above consideration would yield excellent results. 
Children are known to carry the greatest burden of schistosomiasis and soil transmitted 
infections. It is on this basis that the WHO recommended that the school system should be 
the focus in mounting intervention against these disorders. To meet this objective, Bundy 
and Guyatt (1996) summarized the key points to be taken into consideration when 
addressing health education in schools. It should be aimed to: 
 Create awareness about the existence of the diseases, and build a bridge between 
scientific understanding of disease and children’s perception of the disease in their 
every day lives 
 Foster in children an understanding of what is healthy living, and what they can do to 
promote and practice this for themselves and their communities 
 Give children practical skills in recognition of disease in themselves and their families, 
and in how to protect themselves and the community against such diseases, 
 Encourage children’s sense of responsibility for their own health and that of their 
families in the future. 
Kamga et al (2003) assessed a health education strategy in the control of urinary 
schistosomiasis in Cameroon. School children given health education were found to be 
significantly less infected than those who had no health education. The investigators 
concluded that health education through the framework of a school could be adopted as a 
national policy for urinary schistosomiasis control programmes in tropical developing 
countries, planned with school children as full partners, provided that they received 
appropriate orientation. Assessing the knowledge, attitude and practice of residents of 
schistosome endemic areas about schistosomiasis and its control is critical in preventing 
infection. In Nigeria, Useh and Ejezie (1994) showed that 92% of respondents admitted 
knowledge of the disease (in their local language), although none of them knew about the 
aetiologic agent. About 82% of the respondents admitted procuring medication while 15.2% 
did not seek treatment of any kind. Perception of schistosomiasis and water- contact studies 
are very valuable in deploying control approaches. 
8. Development of a schistosome vaccine 
Despite the existence of effective chemotherapeutic agents, progress towards controlling 
schistosomiasis has been slow. Additionally, the possible development of resistance to PZQ 
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and other compounds, rapid re-infection and the overall economic cost, demand that other 
approaches be pursued (Coles et al., 1987). Butterworth et al (1992) argued that the aim of 
vaccination is to reduce morbidity. As in the various animal models, immunity in humans 
appears to be frequently incomplete. “Immune” adults often do become infected, but at 
lower intensities than “susceptible” children. Several investigations have confirmed that the 
severity of clinical disease is dependent on intensity of infection rather than simply the 
presence or absence of infection (Lehman et al.,1976 ; Chen and Mott, 1988) implying that 
even an incomplete immunity may be of considerable value. 
An excellent review on the search for a schistosome vaccine was published not too long ago 
by Wilson and Coulson (2006). These authors rightly chronicled the search for the discovery 
of candidate vaccine molecules to have transited through mining crude extracts, monoclonal 
antibody targets, anti-idiotypes, expression library screening and immunogenicity. The 
early disappointment that was recorded with the vaccination of mice with crude worm 
extracts or purified components, followed by cercarial challenge (Sadun and Lin,1959 ; 
Murrell et al., 1975) and utilizing the idea of concomitant immunity (Smithers and Terry, 
1969) were equally reviewed. Wilson and Coulson (2006) concluded that the sequencing of 
S. mansoni transriptome and genome and the development of proteomic and microarray 
technologies has drastically improved the possibilities for identiflying novel vaccine 
candidates, particularly proteins secreted from or exposed at the surface of schistosomula 
and adult worms. The parameters of an attenuated schistosome vaccine has been evaluated 
in the Olive Baboon (Kariuki et al., 2004). Five exposures of baboons to the attenuated 
schistosome vaccine gave greater protection than three exposures, but this attenuation was 
not sustained when challenge was delayed. Within the scope of the data collected, faecal 
and circulating antigen levels did not accurately predict the observed worm burdens. Levels 
of immunoglobulin G at challenge correlated best with protection, but there was little 
evidence of a recall response. In a related study in baboons, Coulson and Kariuki (2006) 
showed that neither a preceding infection, terminated by chemotherapy, nor an ongoing 
chronic infection affected the level of protection. Whilst IgM responses to vaccination or 
infection were short-lived, IgG responses rose with each successive exposure to vaccine. 
The greatest hope for the discovery of a schistosome vaccine lies in Sh28GST which has 
already undergone Phases 1 and 2 human trials (Capron et al., 2002). No adverse side effects 
were recorded in human recipients and high titres of antibodies were elicited in Phase 1 and 
phase 2 trials (Capron et al., 2005). The results of phase 3 human trials is being awaited. As 
noted by Curwen et al (2004) and Dillion et al (2006), current advances in post-genomic 
techniques are providing new avenues and hope to identify the secreted and surface-
exposed antigens that mediate protection. The search must be sustained as vaccination is the 
most cost-effective and sustainable means of controlling endemic infectious diseases. 
9. Conclusion 
Schistosomiasis would continue to be relevant as one of the Neglected Tropical Diseases 
(NTDs) of public health significance in the tropics because of the attitude of the authorities 
of endemic countries in terms of mobilization of financial resources and political will to fight 
the disease. The hope of control still lies in an integrated approach. For now, the emphasis in 
the short term is based on chemotherapy with PZQ. The reduction in the price of PZQ 
means that millions of infected subjects can afford the drug. The artemisinins have 
performed well in relation to potency and price to PZQ in the control of all forms of 
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schistosomisasis and is recommended particularly in areas where malaria is not endemic. 
Although, clinical resistance to PZQ has not been scientifically proven, there is an urgent 
need to monitor its effectiveness closely as it is likely to remain the drug of choice for the 
foreseeable future. 
The other elements that constitute the integrated approach such as the provision of piped 
water, health education and elimination of snail hosts of schistosomiasis have not been 
implemented with the same zeal as population based chemotherapy 
10. Recommendation 
In order to sustain the fight against schistosomisais, governments of disease endemic areas 
would have to increase funding to health including schistosomiais. A support programme 
that would further reduce the cost of PZQ with increase accessibility would go a long away. 
The activity of PZQ and artemisinins should be closely monitored both in vivo and in vitro 
for the development of resistance. The search for other potent anti-schistosome drugs 
should be pursued vigorously. Other key components like the provision of pipe borne water 
and health education should be put in place by the governments of endemic countries. 
There should be close collaboration between the Ministries of Health, Agriculture, Water 
Resources and Power Supply in the construction of Dams for water supply and provision of 
energy to avoid creating breeding grounds for vectors of diseases. 
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